Cystic fibrosis

Mayo Clinic overview

NIH

Expert Rev Anti Infect Ther. 2003 Dec;1(4):609-18.Links Pseudomonal infection in cystic fibrosis: the battle continues.

Elkin S, Geddes D. Department of Cystic Fibrosis Royal Brompton Hospital London SW3 6NP, UK. sarah.elkin@st-marys.nhs.uk Pseudomonas aeruginosa lung infection is the major cause of morbidity and mortality in patients with cystic fibrosis. Infection usually begins in childhood and is responsible for respiratory failure and death in most patients with cystic fibrosis. The organism triggers an exuberant chronic inflammatory reaction which damages the airways and leads to progressive loss of lung function. Over the last decade significant advances have been made in the understanding of the pathophysiology of cystic fibrosis airways disease. These should assist the development of new and better therapies to treat this pathogen. This review provides an overview of pseudomonal infection in cystic fibrosis, including mechanisms by which the bacteria may colonize the cystic fibrosis airway, persistence of pseudomonal infection and the biofilm A structured community of microorganisms encapsulated within a self-developed protective matrix and living together. mode of growth. Available treatments and possible novel approaches to therapy will be discussed. ¹⁾

Bacterial colonization of the airways of the infant with cystic fibrosis is usually established early in life, and, once established, is difficult to eradicate and is associated with progressive lung disease. ²⁾

ChIP-seq reveals the global regulator AlgR mediating cyclic di-GMP synthesis in Pseudomonas aeruginosa ³⁾

<DiseaseHierarchy>

GETCONTENT

• legacy content